← All trials
NCT06576375
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 2, 2024
- Primary completion
- Jan 31, 2025
- Completion date
- Jan 31, 2025
- First posted
- Aug 28, 2024
- Last posted
- Oct 22, 2024
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Future University in EgyptLead sponsor
- Future University in EgyptSponsor investigator
- October 6 UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.